Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

re. VYVANSE sales were up 32% and INTUNIV sales grew 50%.

The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world. In addition to initiating Phase 3 clinical trials for VYVANSE as adjunctive therapy in Major Depressive Disorder (MDD), we're releasing highlights of exploratory data showing that cognition and executive function were improved in patients with MDD taking VYVANSE as adjunctive therapy. We've also released positive new clinical data related to our Phase 3 European ADHD clinical program. Overall, we've increased investment in our R&D programs by 21% compared to Q3 2010, and still generated good earnings growth and strong cashflows.

Over the course of the year we've seen market expectations for Shire's 2011 earnings rise, with further increases in the last quarter. After these good third quarter results, and after taking account of the lower royalty income that we will be recording in future periods, we remain on track to meet these increased expectations. We anticipate that this will be another very good year for Shire as we deliver strong sales and continue our investment program for sustained future growth."

FINANCIAL SUMMARY

Third Quarter 2011 Unaudited Results

Q3 2011 Q3 2010 Non Non US GAAP Adjustments GAAP US GAAP Adjustments GAAP $M $M $M $M $M $M Total revenues 1,086 - 1,086 874 - 874 Operating income 255 86 341 156 142 298 Diluted earnings per ADS $1.02 $0.26 $1.28 $0.52 $0.64 $1.16

  • Product sales were up 28% to $1,018 million (Q3 2010: $794 million) as our existing products continued to demonstrate strong growth even when compared to the very good performance in Q3 2010. In Q3 2011 we recognized the first full quarter of DERMAGRAFT® sales which contributed six percentage points to product sales growth. On a constant exchange
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... 11 VIA Pharmaceuticals,(Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today that,Lawrence ... Stewart, senior,vice president and chief financial officer, will ... Company 28th Annual Health Care Conference on,Tuesday, March ...
... FRANCISCO, Calif., March 11 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the discovery, development and commercialization of,novel small-molecule therapeutics, ... year ended December 31, 2007., Total revenue ... million, with a,net loss of $8.8 million. Total ...
... March 11 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... today announced that Dr. Leslie J. Browne,President and Chief ... and Company 28th Annual Health Care Conference.,The conference will ... Boston Marriott,Copley Place, Boston, Massachusetts., Dr. Browne,s presentation ...
Cached Biology Technology:Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 10Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 2Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 3
(Date:10/18/2014)... a sample of patients with undiagnosed, suspected genetic conditions, ... with a higher molecular diagnostic yield than traditional molecular ... JAMA . The study is being released to coincide ... , Exome sequencing, which sequences the protein­coding region of ... material present in a cell or organism), has been ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... N.H. New research from Plymouth State University and ... bleeding horseshoe crabs for biomedical purposes causes short-term changes ... crabs, population decline in parts of the east coast. ... the blue blood from almost half a million living ...
... (Feb. 19, 2014) -- There are more than a trillion ... our brains. Each of these neurons contains millions of proteins ... form the complex networks of the brain still remains as ... For the first time, a group of scientists has been ...
... its food plants and parasitoids, has been going on for ... (ACG), a protected area of approximately 1200 km2 in ... of moths and butterflies are estimated to live in ACG. ... also numbering thousands of species. However, most of those wasps ...
Cached Biology News:Biomedical bleeding affects horseshoe crab behavior 2Biomedical bleeding affects horseshoe crab behavior 3Watching how the brain works 2Almost 200 new species of parasitoid wasps named after local parataxonomists in Costa Rica 2
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: